Lantheus Holdings (NASDAQ: LNTH) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lantheus (LNTH – Research Report) and Argenx Se ...

Q4 2024 Earnings Call Transcript February 26, 2025 Operator: Good morning. Welcome to the Lantheus Fourth Quarter and Full ...

In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Lantheus (LNTH – Research Report), with a price ...

Lantheus Holdings Inc (LNTH) reports robust sales growth for PYLARIFY and DEFINITY, while navigating increased operating ...

William Blair analyst Andy Hsieh reiterated a Hold rating on Lantheus (LNTH – Research Report) today. The company’s shares opened today at ...

Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) jumped 19.8% in the morning session after the company ...

Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) jumped 19.8% in the morning session after the company ...

Welcome to the Lantheus Fourth Quarter and Full Year 2024 Conference Call. [Operator Instructions]. This call is being recorded and a replay will be available in the Investors section of the company's ...

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported Q4 CY2024 results topping the market’s revenue ...

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 ...

Reports Q4 revenue $391.1M, consensus $376.18M. “2024 was a groundbreaking year for Lantheus (LNTH), as our radiodiagnostic, PYLARIFY, reached ...